Disease · HP_0030242
Portal vein thrombosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Portal vein thrombosis. Diseases, record HP_0030242. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0030242
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Portal vein thrombosis
- Open Targets ID
- HP_0030242
- Other names
- Blood clot in portal vein
- Highest stage of its drugs
- Phase 3, for 6 of its 16 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs16
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RIVAROXABAN | CHEMBL198362 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| WARFARIN | CHEMBL1464 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HEPARIN | CHEMBL4650299 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROPRANOLOL | CHEMBL27 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SORAFENIB | CHEMBL1336 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| YTTRIUM Y-90 | CHEMBL4650364 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DABIGATRAN | CHEMBL48361 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ENOXAPARIN | CHEMBL1201685 | Oligosaccharide | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CHLOROTRIANISENE | CHEMBL1200761 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| LENVATINIB | CHEMBL1289601 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 16
See all 16 drugsTargets22
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| F10 | Coagulation factor X | 2 | Coagulation factor X inhibitor | Phase 3 | https://conductscience.org/library/genes/2159 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| SERPINC1 | Antithrombin-III | 2 | Antithrombin-III activator | Phase 3 | https://conductscience.org/library/genes/462 | Drugs and targets |
| VKORC1 | Vitamin K epoxide reductase complex subunit 1 | 2 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/79001 | Drugs and targets |
| ADRB1 | Beta-1 adrenergic receptor | 1 | Beta-1 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 1 | Beta-2 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 1 | Serine/threonine-protein kinase B-raf inhibitor | Phase 3 | https://conductscience.org/library/genes/673 | Drugs and targets |
| ESR2 | Estrogen receptor beta | 1 | Estrogen receptor beta modulator | Phase 2 | https://conductscience.org/library/genes/2100 | Drugs and targets |
1 to 10 of 22
See all 22 targetsTrials18
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein | Phase 3 | 36 | 2019-10-29 | Hepatocellular Carcinoma | YTTRIUM Y-90 | Its record names the disease | ClinicalTrials.gov |
| NCT01482442 | SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma | Phase 3 | 496 | Liver Carcinoma | SORAFENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02335580 | Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis | 475 | Liver Cirrhosis, Portal Vein, Venous Thrombosis, Varicose Veins, Hemorrhage | SOMATOSTATIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT07602062 | Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis | Not applicable | 175 | Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding | RIVAROXABAN | Its record names the disease | ClinicalTrials.gov | |
| NCT06818279 | Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis | Phase 2/3 | 120 | Portal Vein Thrombosis, Liver Cirrhosis | DABIGATRAN, ENOXAPARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02853526 | TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV | Phase 3 | 100 | Portal Vein, Cavernous Transformation of, Portal Vein Thrombosis, Liver Cirrhosis, Bleeding Esophageal Varices | PROPRANOLOL, WARFARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03631147 | The Effect of Rifaximin on Portal Vein Thrombosis | Not applicable | 96 | Cirrhosis, Portal Vein Thrombosis | RIFAXIMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04433481 | Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis | Not applicable | 84 | Liver Cirrhosis, Portal Vein Thrombosis | DABIGATRAN | Its record names the disease | ClinicalTrials.gov | |
| NCT06319131 | Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT | Not applicable | 84 | Portal Vein Thrombosis | NADROPARIN CALCIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT02991612 | Rifaximin in Patients With Gastroesophageal Variceal Bleeding | Not applicable | 80 | Cirrhosis, Esophageal and Gastric Varices, Gastrointestinal Hemorrhage | RIFAXIMIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| TheraSphere vs Sorafenib: deaths from any cause | 15 of 15 | 16 of 16 | 31 | NCT01887717 | Trial comparisons |
| TheraSphere vs Sorafenib: serious adverse events | 0 of 15 | 12 of 16 | 31 | NCT01887717 | Trial comparisons |
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0030242
GET https://conductscience.org/api/diseases/v1/HP_0030242/targets?page=2